Abstract
Genomics is transforming the pharmaceutical industry. Companies are moving
from drug discovery and development based on medicinal chemistry to the design
of drugs based on information provided by genomics. Virtually all of the major
pharmaceutical houses have either formed partnerships with genomics firms that
began to emerge in the early 1990s or have created in house genomics
divisions. The aim of this TriMark Publications study is to provide in depth
information on the developing market for genomics products and services.
The report will include detailed market analyses and discussions of industry
trends in order to assess the impact of genomics on the current and emerging
pharmaceutical and diagnostic markets. Forecasts and trends were developed
from interviews with industry sources, as well as from an assessment of
available and emerging technologies. The report focuses on how researchers are
applying new genomic approaches to drug discovery and development, and on how
these technologies can be used most effectively and in a high throughput
capacity. Case studies analyzing particular applications of genomic
technologies to specific disease related research are provided, and future
trends and developments are forecasted. Information to prepare this study was
derived from interviews with product managers, marketing strategists, research
executives and others. These individuals are employed at leading genomics
firms or in pharmaceutical and biotechnology companies that either contract
with these firms or have developed in house genomics capabilities.
View Cart
